Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
- PMID: 26206268
- DOI: 10.1016/j.vaccine.2015.07.024
Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
Abstract
Background: We assessed the risk of spontaneous abortion (SA) after inadvertent exposure to HPV-16/18-vaccine during pregnancy using an observational cohort design.
Methods: The study population included women aged 15-25 years registered with the Clinical Practice Research Datalink General Practice OnLine Database in the United Kingdom (UK), who received at least one HPV-16/18-vaccine dose between 1st September 2008 and 30th June 2011. Exposed women had the first day of gestation between 30 days before and 45 days (90 days for the extended exposure period) after any HPV-16/18-vaccine dose. Non-exposed women had the first day of gestation 120 days-18 months after the last dose. SA defined as foetal loss between weeks 1 and 23 of gestation (UK definition).
Results: The frequency of SA was 11.6% (among 207 exposed) and 9.0% (632 non-exposed), women: hazard ratio (HR) adjusted for age at first day of gestation 1.30 (95% confidence interval: 0.79-2.12). Sensitivity analysis per number of doses administered (-30 to +45-day risk period) showed a HR for SA of 1.11 (0.64-1.91) for 18/178 women with one dose during the risk period versus 2.55 (1.09-5.93) in 6/29 women with two doses within a 4-5 weeks period. The proportion of pre-term/full-term/postterm deliveries, small/large for gestational age infants, and birth defects was not significantly different between exposed and non-exposed women. Results were consistent using a (United States) SA definition of foetal loss between weeks 1-19 and/or the extended risk period.
Conclusion: There was no evidence of an increased risk of SA and other adverse pregnancy outcomes in young women inadvertently HPV-16/18-vaccinated around gestation. Nevertheless, women who are pregnant or trying to become pregnant are advised to postpone vaccination until completion of pregnancy.
Keywords: Human papillomavirus vaccine; Mathematical model; Pregnancy; Safety; Spontaneous abortion; Vaccine.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of spontaneous abortion: a systematic review and meta-analysis.BMC Pregnancy Childbirth. 2019 Aug 19;19(1):302. doi: 10.1186/s12884-019-2425-1. BMC Pregnancy Childbirth. 2019. PMID: 31426762 Free PMC article.
-
Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.Hum Vaccin Immunother. 2016 Nov;12(11):2862-2871. doi: 10.1080/21645515.2016.1199308. Epub 2016 Jul 18. Hum Vaccin Immunother. 2016. PMID: 27428517 Free PMC article.
-
Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.Pediatr Infect Dis J. 2014 Dec;33(12):1255-61. doi: 10.1097/INF.0000000000000460. Pediatr Infect Dis J. 2014. PMID: 24978856 Clinical Trial.
-
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.Hum Vaccin Immunother. 2014;10(7):1795-806. doi: 10.4161/hv.28702. Hum Vaccin Immunother. 2014. PMID: 25424785 Free PMC article. Clinical Trial.
-
AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.Drugs. 2011 Mar 5;71(4):465-88. doi: 10.2165/11206820-000000000-00000. Drugs. 2011. PMID: 21395359 Review.
Cited by
-
Peri-conceptional or pregnancy exposure of HPV vaccination and the risk of spontaneous abortion: a systematic review and meta-analysis.BMC Pregnancy Childbirth. 2019 Aug 19;19(1):302. doi: 10.1186/s12884-019-2425-1. BMC Pregnancy Childbirth. 2019. PMID: 31426762 Free PMC article.
-
Predictors of Maternal Death Among Women With Pulmonary Hypertension in China From 2012 to 2020: A Retrospective Single-Center Study.Front Cardiovasc Med. 2022 Apr 18;9:814557. doi: 10.3389/fcvm.2022.814557. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35509273 Free PMC article.
-
A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.Hum Vaccin Immunother. 2019;15(7-8):1970-1979. doi: 10.1080/21645515.2019.1625644. Epub 2019 Jul 17. Hum Vaccin Immunother. 2019. PMID: 31268383 Free PMC article. Clinical Trial.
-
Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.Vaccine. 2023 Jun 7;41(25):3688-3700. doi: 10.1016/j.vaccine.2023.03.038. Epub 2023 Mar 27. Vaccine. 2023. PMID: 37012114 Free PMC article.
-
Seasonal influenza vaccine exposure in pregnancy: 5-year results from a pregnancy registry.Hum Vaccin Immunother. 2022 Dec 31;18(1):1932213. doi: 10.1080/21645515.2021.1932213. Epub 2021 Jun 3. Hum Vaccin Immunother. 2022. PMID: 34082643 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical